### **Overview** FDC Limited (FDC Ltd) is a leading, fully integrated Indian pharmaceutical company with over **85 years of legacy**, established in 1936 and incorporated in 1940. Headquartered in India, the company is committed to advancing affordable, high-quality healthcare globally. FDC operates across **API development, formulation manufacturing, contract manufacturing, nutraceuticals, functional foods, and biotechnology**, with a strong focus on innovation, regulatory compliance, and patient-centric solutions. FDC is a pioneer in key therapeutic segments, notably as the **global leader in Oral Rehydration Salts (ORS)** through its flagship brand *Electral*, and a major player in **ophthalmic products, anti-infectives, cardiovascular, anti-diabetic, and nutraceuticals**. The company markets over **300 products in India** and exports to **over 50 countries** across **Europe, Asia-Pacific, Africa, the Middle East, Latin America, and the CIS region**. --- ### **Strategic Positioning & Growth Drivers** #### **1. Geographic Presence & Global Expansion** - **Global Reach**: FDC serves markets in the US, UK, Australia, Malaysia, South Asia, Africa (Ethiopia, Tanzania, Zimbabwe), New Zealand, and several CIS and Middle Eastern nations. - **Export-led Growth**: Exports constitute ~13–15% of consolidated revenue, with the **US** being the largest international market, followed by the **UK, Africa, and Australia**. - **Regulatory Advantage**: Manufacturing facilities are approved by **US-FDA, UK-MHRA, WHO-GMP, PMDA (Japan), ANVISA (Brazil), TGA (Australia), EDQM, and NAFDAC (Nigeria)**, enabling access to **highly regulated markets**. - **Recent Expansion**: - Registered **I Lube Eye Drops (Medical Device)** in Malaysia, entering the **CE-marked ophthalmic devices market**. - Launched ophthalmic products in **Uzbekistan, Oman, the West Indies, and New Zealand**. - Strengthening presence in **Africa** with the *Electral Zinc Kit*, *Electral Ready-to-Drink*, and *Electral Z* powder. - Strategic focus on **non-US markets** such as **UK, Australia, Malaysia, Middle East, and African nations** to diversify export dependency. #### **2. Financial Performance (FY 2024–25)** - **Total Revenue**: ₹32,108 crore (+8.5% YoY), crossing the ₹32,000 crore milestone. - **India Formulations**: Contributed **84%** of sales, growing **14.4% YoY**—driven by flagship brands and robust domestic demand. - **API Segment**: Achieved **21% YoY growth** (FY25 revenue: ₹112 crore), reflecting strong momentum in in-house API production and global demand. - **Export Formulations**: Declined **25.6% YoY** due to temporary US regulatory headwinds, expected to recover in FY2025–26. - **Domestic Market Focus**: ~75% of revenue originates from India, with sustained growth in chronic and preventive therapies. --- ### **Core Business Segments & Product Portfolio** #### **1. Key Therapeutic Areas** - Anti-infectives (Zifi, Flemiclav) - Cardiovascular (Amodep-TM/TMH) - Anti-diabetics (Sitagliptin) - Gastroenterology (Enteroplus) - Ophthalmology (Timolol, Latanoprost, Moxifloxacin, Olopatadine) - Paediatrics (Zifi Infant, taste-masked formulations) - Nutraceuticals & Functional Foods (Enerzal, Vitcobin, Zefrich) - Dermatology (Zocon, Cotaryl-3D) #### **2. Flagship Brands** - **Electral** (ORS): Market leader in India (~70% volume share), expanded with Zinc kit and RTD versions in Africa. - **Zifi** (Cefixime): #1 brand in its category (market share ~24–49% in segments). - **Enerzal** (Energy Drink): Category leader (~40% market share), expanded with *Enerzal Zero*, Tetra Paks, and PET bottles. - **Zocon**: Key dermatology brand with 71% growth in select variants. - **Vitcofol**: Leading multivitamin supplement with strong physician traction. --- ### **R&D & Innovation** FDC’s R&D is structured around **formulations, synthetic APIs, nutraceuticals, and biotechnology**, with dedicated centers in **Mumbai (Kandivali, Jogeshwari)**, **Aurangabad**, and **Roha**. #### **Key Developments (FY 2024–25)** - **Patents & Intellectual Property**: - Filed **4 new patents**, including a **provisional patent for a stable, low-impurity ophthalmic formulation**. - Achieved **Reference Standard (RS) status for Cefixime tablets**—a regulatory milestone strengthening its anti-infective portfolio. - **Advanced Drug Delivery Systems**: - Developed **dual-release tablets, taste-masked pediatric dispersible tablets, ready-to-use suspensions, and sachet-based nutrition blends**. - Utilized **bilateral tablet technology** and **MUPS (Multiparticulate Pellets)** for controlled release. - **AI Integration**: - Leveraged **AI in literature reviews and formulation design** to accelerate development timelines and reduce costs. - Deployed **real-time analytics and performance dashboards** for commercial optimization. - **Peptide & Biologics R&D**: - Synthesizing **semaglutide, tirzepatide, linaclotide, and teriperatide** for diabetes, obesity, and osteoporosis. - **Filgrastim (G-CSF) process validation underway**—produced 3 batches at Jogeshwari biotech facility; final filling in pre-filled syringes at DCGI-approved site for stability and clinical trials. - **Reteplase biologic project** deemed non-viable internally; exploring **external partnerships** for future biotech candidate development. --- ### **Manufacturing & Capabilities** FDC operates **seven state-of-the-art manufacturing facilities** across India: - **Waluj, Sinnar, Roha (Maharashtra)** - **Baddi (Himachal Pradesh)** - **Verna (Goa)** #### **Capacity Highlights** - **Waluj Facility**: - 156 MT annual API capacity. - Monthly output: 17.5 million tablets, 1 million oral liquid bottles, 3 million ophthalmic LDPE bottles, 7.5 million ORS sachets. - **BFS (Blow-Fill-Seal)**: Used for **sterile ophthalmic and oral liquids**, minimizing contamination risk. - **Certifications**: All plants are **US-FDA, MHRA, WHO-GMP, ISO 14001:2015 (Environment), and ISO 45001:2018 (Occupational Health & Safety)** compliant. #### **Backward Integration** - **In-house API production** for Timolol, Latanoprost, Flurbiprofen, Dorzolamide, Cephalosporins, and others. - Ensures **cost efficiency, quality control, and regulatory consistency**. --- ### **Go-to-Market & Commercial Strategy** #### **1. Sales & Distribution** - **Domestic**: - Field force of **~3,600 medical representatives**, organized into 10 sales divisions. - Strengthened coverage in **Tier 2 & 3 cities** and improved penetration in chronic care segments. - **International**: - Wholly-owned subsidiaries in **UK (FDC Internationals UK)** and South Africa. - Branch offices and distribution partners in Africa, Latin America, and Asia. - Preferred supplier to **UNICEF, MSF (Doctors Without Borders), WHO, and IDA**. #### **2. Digital Transformation** - Launched a **hybrid CRM platform** enabling e-detailing, video consultations, and in-person engagement with HCPs. - Real-time analytics for **sales tracking, demand forecasting, inventory management, and performance monitoring**. - Digitized R&D with **electronic lab notebooks (21 CFR Part 11 compliant)**. #### **3. Consumer Wellness & Brand Strategy** - Transitioning **Electral** and **Enerzal** from prescription to **DTC (direct-to-consumer) wellness brands**. - Expanded formats: **Tetra Paks, PET bottles, flavored powders, zero-sugar variants**. - Launched **new nutraceuticals**: *AV-Uti* (urinary health) and *Vitcobin Multivitamin Syrup*.